Biotech companies like Seaport Therapeutics and Gilgamesh Pharmaceuticals are developing next-generation psychedelics to address mental health issues, seeking to overcome limitations of traditional psychedelics like psilocybin and LSD.
Sam Banister of Psylo notes the recent surge in funding and interest towards psychedelic research, contrasting the past fringe status with present multi-billion dollar investments and numerous companies working in the field.
Collection
[
|
...
]